Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics (NASDAQ:APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.
Cancer Trial Data
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer during the trial, with a 50% reduction in target lesion measurements. Additionally, CA-125 tumor biomarker levels dropped significantly, from 362 U/mL at baseline to 47 U/mL, indicating promising anti-tumor activity.
Enrollment in the 220 mg dose cohort continues, and Aprea plans to expand the study to include more patients with specific genetic alterations. The ongoing trial aims to evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026.
Analyst Consensus & Recent Actions
The stock carries a Buy Rating. Recent analyst moves include:
- Wedbush: Outperform (Lowers Target to $7.00) (Feb. 10)
- HC Wainwright & Co.: Buy (Lowers Target to $4.00) (Jan. 29)
APRE Price Action: Aprea Therapeutics shares were up 16.62% at $0.70 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold prices rise Rs 1,500/10g; silver up Rs 3,100/kg ahead of US economic data, softer yields. Buy, sell or hold?
The Shopify Stock Rally Isn't Done: Chart of the Week -- Barrons.com
By Doug Busch Shopify is no longer a pandemic-era growth story that simply failed to slow down. It is compounding at a pace few software platforms its size still manage. In the second quarter of 2026, sales on its platform rose 32%. That was the fifth straight quarter of growth exceeding 30%. Merchants are also using more of Shopify's own tools, from payments to Shop Pay, and new channels like AI shopping agents are starting to increase demand. The simple bull case is that the stock already commands a huge share of independent online commerce, and that position should become more valuable as more buying moves through its checkout. A rule of market mechanics is that the vast majority of an individual security's gain is driven by its underlying sector. Within technology, software has staged a robust recovery, joining semiconductors to power the broader sector higher. The iShares Expanded Tech-Software Sector ETF has maintained an upward trajectory since its mid-April lows, though the advance from $74 to $112 has been choppy as bulls repeatedly stepped in to defend when necessary. Breadth across large-cap software has expanded significantly, with 24 constituents surging over 20% over the past three months. During that same three-month window, Shopify generated outstanding relative strength, advancing 36%, more than doubling the IGV's 17% gain over the same period. Expect the stock's outperformance to persist as software momentum broadens. Let's examine the daily and monthly charts to outline the technical drivers behind this thesis. Looking at the daily chart, the ratio chart against the IGV shows persistent outperformance extending back to mid-May. The stock is riding an eight-session winning streak, during which price action cleared a double-bottom-with-handle pivot at $151.39. Within this broader base, the stock recorded a bullish golden cross in late August and successfully filled its Sept. 10 price gap, tracing back to its Aug. 4 session, the day before a powerful earnings reaction sent the stock surging 17% hi
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
TRexBio: IPO Of 8.3M Shares Priced at $14.00 Each >TRXB
Crypto prices
More
